Literature DB >> 20030254

[Prion disease surveillance in Japan: analysis of 1,241 patients].

Masahito Yamada1, Ichiro Nozaki, Tsuyoshi Hamaguchi, Moeko Noguchi-Shinohara, Tetsuyuki Kitamoto, Yosikazu Nakamura, Takeshi Sato, Hidehiro Mizusawa.   

Abstract

The Creutzfeldt-Jakob Disease (CJD) Surveillance Committee has identified 1,241 patients with prion diseases during 1999-2009, including 953 with sporadic CJD (sCJD) (76.8%), 207 with genetic prion diseases (16.7%), 78 with environmentally acquired prion diseases (6.3%), and 3 with unclassified CJD. Among atypical cases of sCJD, most common was MM2 type including the cortical and thalamic forms. The genetic cases included 84 with a PrP V180I mutation (40.6%), 37 with a P102L mutation (17.9%), 34 with a E200K mutation (16.4%), 32 with a M232R mutation (15.5%), 4 with a P105L mutation (1.9%), and so on. The environmentally acquired cases included 77 with dura mater graft-associated CJD (dCJD) and one with variant CJD (vCJD). Combined with the results by the previous surveillance systems, a total number of dCJD in Japan was 135. The vCJD patient had a history of short stay in the UK and presented with periodic electroencephalogram in the late stage. Although there was no evidence of association of surgical procedures or blood transfusion with sCJD, 4.5% of the sCJD patients underwent operations after the onset of sCJD, including neurosurgical for 0.8% and ophthalmic for 1.9%, requiring more attention on prion diseases to reduce the iatrogenic risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20030254     DOI: 10.5692/clinicalneurol.49.939

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  1 in total

1.  Dura mater graft-associated Creutzfeldt-Jakob disease: the first case in Korea.

Authors:  Hye Lim Kim; Ju Young Do; Han Jeong Cho; Yong-Chul Jeon; Seok Joo Park; Hyeo Il Ma; Jun Ho Song; Yul Lee; Hyun Choi; Kyung Chan Choi; Yong Sun Kim; Inga Zerr; Kai Kallenberg; Yun Joong Kim
Journal:  J Korean Med Sci       Date:  2011-10-27       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.